KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Intangibles: 2009-2024

Historic Intangibles for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $4.4 billion.

  • Teva Pharmaceutical Industries' Intangibles fell 17.24% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year decrease of 17.24%. This contributed to the annual value of $4.4 billion for FY2024, which is 17.99% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Intangibles is $4.4 billion, which was down 17.99% from $5.4 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Intangibles peaked at $8.9 billion during FY2020, and registered a low of $4.4 billion during FY2024.
  • Moreover, its 3-year median value for Intangibles was $5.4 billion (2023), whereas its average is $5.4 billion.
  • Data for Teva Pharmaceutical Industries' Intangibles shows a maximum YoY decreased of 20.56% (in 2020) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Intangibles (Yearly) stood at $8.9 billion in 2020, then dropped by 16.33% to $7.5 billion in 2021, then declined by 16.02% to $6.3 billion in 2022, then fell by 14.08% to $5.4 billion in 2023, then fell by 17.99% to $4.4 billion in 2024.